Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe

Nara Melikyan; Helena Huerga; Hakob Atshemyan; Ohanna Kirakosyan; Narina Sargsyants; Tsovinar Aydinyan; Nora Saribekyan; Naira Khachatryan; Izabella Oganezova; Joana Falcao; Suna Balkan; Cathy Hewison

doi:10.1093/ofid/ofaa653

Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe

Open Forum Infect Dis. 2021 Jan 4;8(2):ofaa653. doi: 10.1093/ofid/ofaa653. eCollection 2021 Feb.

Authors

Affiliations

¹ Epicentre, Paris, France.
² Médecins Sans Frontières, Yerevan, Armenia.
³ Ministry of Health, Yerevan, Armenia.
⁴ Médecins Sans Frontières, Paris, France.

Abstract

We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.

Keywords: chronic hepatitis C; direct-acting antiviral drugs; multidrug-resistant tuberculosis; sofosbuvir; virus.